At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
LAT8881 +1 moredrug
Likely dose
LAT8881 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine
In Brief
A Phase 2 clinical trial evaluating LAT8881 and Placebo for Acute Migraine. Completed, enrolled 21 participants across 3 sites.
Detailed Summary
This is a randomised, placebo controlled, double blind, crossover proof of concept study to investigate the efficacy and safety of oral LAT8881 in acute migraine, with or without aura.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Migraine
CountriesAustralia
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartSep 2019
First PostedNov 2019
Primary CompletionFeb 2020
Study CompletionApr 2020
TodayJul 2026
First PostedNov 6, 2019
Enrollment StartSep 24, 2019
Primary CompletionFeb 15, 2020
Study CompletionApr 10, 2020
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.7 years ago
Interventions
LAT8881drug
Two 30 mg capsules of LAT8881
Placebodrug
Two capsules of placebo